Intervertebral disc (IVD) degeneration (IDD) is the most common cause leading to low back pain (LBP), which is a highly prevalent, costly, and crippling condition worldwide. Current treatments for IDD are limited to treat the symptoms and do not target the pathophysiology. Tumor necrosis factor-α (TNF-α) is one of the most potent pro-inflammatory cytokines and signals through its receptors TNFR1 and TNFR2. TNF-α is highly expressed in degenerative IVD tissues, and it is deeply involved in multiple pathological processes of disc degeneration, including matrix destruction, inflammatory responses, apoptosis, autophagy, and cell proliferation. Importantly, anti-TNF-α therapy has shown promise for mitigating disc degeneration and relieving LBP. In this review, following a brief description of TNF-α signal transduction, we mainly focus on the expression pattern and roles of TNF-α in IDD, and summarize the emerging progress regarding its inhibition as a promising biological therapeutic approach to disc degeneration and associated LBP. A better understanding will help to develop novel TNF-α-centered therapeutic interventions for degenerative disc disease.
Introduction
Low back pain (LBP) has an extremely high incidence. It is estimated that as much as 84% of the worldwide population suffer from LBP at some point in their lifetime, while 10% are chronically disabled [1] . As the second most common cause of doctor visits, LBP has become a major factor affecting quality of life and leads to an enormous socioeconomic burden. There are many causes in the etiology of LBP, among which intervertebral disc (IVD) herniation and IVD degeneration (IDD) are the most common diagnoses and targets for intervention [2] . IDD is a multifactorial process characterized by cellular and biochemical changes in disc tissues that lead to structural failure, and it is currently attributed to the interaction between environmental and genetic factors (Fig. 1) . However, environmental factors including vibration, mechanical loading, physical activities, and smoking are responsible for only a small portion of IDD [3] [4] [5] [6] . Conversely, genetic heredity is the predominant risk factor for degenerative disc disease and is believed to cause >70% of cases [7] . Current therapeutic options for IDD include medications, steroid injection, physical therapy, and surgery. If conservative treatments fail, then surgery has to be performed to relieve LBP [8, 9] . However, all of these interventions are limited to improve symptoms and do not aim to impede the pathophysiological processes involved in IDD. Recently, some biological strategies capable of preventing early disc degeneration by promoting extracellular matrix (ECM) repair and regeneration have been developed [10] [11] [12] . However, their long-term effects still have to be evaluated in the clinical setting. Thus, a greater understanding of IDD pathology is important to optimize treatment strategies and develop novel anti-IDD drugs.
Multiple pathological changes have been observed in the progression of IDD, each of which provides insights into the disease process. As the largest avascular structure in the body, a normal disk is made up of three morphologically distinct regions: nucleus pulposus (NP), annulus fibrosus (AF), and cartilaginous endplates (CEPs), as shown in Fig. 1 . The compositions and functions in load bearing are different between NP and AF. The NP is a gelatinous matrix that is composed predominantly of Type II collagen (Col II) and proteoglycans, with high water content. This arrangement contributes to its hydrostatic pressurization and resistance to compressive forces [13] . The AF is a thick and dense structure, which is divided into the outer and inner annulus. The ECM in outer annulus is dominated by Type I collagen (Col I) and contains relatively low amounts of proteoglycans and water. The inner annulus is more fibrocartilaginous and is composed of both Col I and Col II, with a higher proteoglycan content. With the progression of degeneration, Col II content gradually decreases, leading to a reduced ratio of Col II to Col I. Moreover, the distribution of collagens is altered, with more Col II appearing in the outer annulus. Col I forms stronger collagen fibrils within the inner annulus and NP [14] .
Tumor necrosis factor (TNF)-α, an important member of the TNF superfamily of ligands, is a pleiotropic pro-inflammatory cytokine. Annular puncture with TNF-α injection has been shown to enhance painful behavior with disc degeneration in vivo [15] . In a porcine model, lumbar discs receiving exogenous TNF-α injection display degenerative changes with annulus fissure, cell cluster, NP matrix loss, vascularization, and interleukin (IL)-1β expression in the outer annulus, suggesting TNF-α as a driver in disc degeneration [16] . Moreover, inflammatory responses and ECM degradation elicited by TNF-α are considered as critical events in the process of IDD and associated LBP [17] . In this review, we summarize the expression patterns and roles of TNF-α in IDD and describe the recent progress regarding its inhibition as a promising biological therapeutic approach for disc degeneration.
Structure and Synthesis of TNF-α
The human TNF-α gene was first cloned in 1984 and maps within the major histocompatibility complex to Chromosome 6p21.3. As a single copy gene, it spans~3 kb and is made up of four exons and three introns. Of note, over 80% of the mature TNF-α sequence are encoded in the last exon [18] . The first and second exons predominantly contain the leader peptide sequence. The transcriptional activation of the TNF-α gene is involved in multiple regulatory elements whose functional properties vary between stimuli and cell types. In rat NP cells, CCAAT/enhancer binding protein β (C/EBPβ) increases the levels of TNF-α, which is mediated by the extracellular signalregulated kinase 1/2 (ERK1/2) and p38 mitogen activated protein kinase (MAPK) pathways [19] . In monocytes and macrophages, lipopolysaccharide (LPS) induces TNF-α expression by activating early growth response factor-1 (Egr-1) [20] , activator protein-1 (AP-1) [21] , MAPK [22] , and nuclear factor-κB (NF-κB) [23] . In neonatal rat cardiac fibroblasts, the activating transcription factor-2 (ATF-2)/c-Jun signaling pathway, but not NF-κB, is required for the up-regulation of TNF-α expression induced by angiotensin II and LPS [24] . When being exposed to LPS, cardiomyocytes display a significant increase in TNF-α production, which is mediated by the reactive oxygen species (ROS)/c-Src/histone deacetylase 3 [25] and ROS/MAPK pathways [26, 27] . Thus, the expression of TNF-α is regulated predominantly at the transcriptional level. However, TNF-α production is also regulated at the post-transcriptional level via the UA-rich sequence in the 3′ untranslated region of its mRNA [28] .
TNF-α is synthesized as a monomeric Type II protein containing 233 amino acid (27 kDa), and then it is arranged in stable homotrimers as transmembrane TNF-α (tmTNF-α). Three monomers associate around a 3-fold axis to form a compact bell-shaped trimer. This structure is typical for most members of the TNF family but comparison to known protein structures also shows structural homology to several viral coat proteins [29] . Interestingly, tmTNF-α can be also cleaved by metalloprotease TNF-α-converting enzyme (TACE), also known as ADAM metallopeptidase domain 17 (ADAM17), leading to the formation of a 51-kDa soluble homotrimer (sTNF-α) [30, 31] . Both tmTNF-α and sTNF-α are biologically active, although monomeric and dimeric forms also exist.
TNF-α Signal Transduction
TNF-α acts through two transmembrane glycoprotein receptors: TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), which are the basic members of the TNFR superfamily (Fig. 2) . A hallmark of this superfamily is the cysteine-rich regions in their extracellular domain, including six highly-conserved cysteine residues [32] . Both TNFR1 and TNFR2 contain four cysteine-rich repeats. Like tmTNF-α and sTNF-α, they also form a trimeric structure. TNFR1 is constitutively expressed in the majority of cell types and seems to be the key mediator of TNF-α signaling. In contrast, TNFR2 is highly regulated and predominantly found in immune cells, suggesting that this receptor plays a major role in modulation of immune function [33] . The extracellular domains of both receptors can also be cleaved from the cell surface, which are then released in their soluble forms and eventually neutralize the actions of TNF-α [34] . This cleavage is performed by TACE in the TNFR2 [35] , whereas the proteolytic enzyme releasing sTNFR1 is still unknown. Thus, TACE may exert either pro-or anti-inflammatory effects, depending on whether it cleaves and subsequently releases sTNF-α or sTNFR2, respectively. TNF-α binds to both TNFR1 and TNFR2 with high affinity. tmTNF-α can interact with either receptor, while sTNF-α can only interact with TNFR1.
TNFR1-dependent signaling pathways
TNFR1 contains a cytoplasmic death domain (DD). In the absence of a ligand, DD interacts with silencer of death domain (SODD) to keep TNFR1 in an inactive state [36] . Upon tmTNF-α or sTNF-α stimulation, SODD is released from the TNFR1/SODD complex, and TNFR1 becomes active (Fig. 2) . TNFR1 then binds to an adaptor protein TNF receptor-associated death domain (TRADD), which is followed by recruitment of additional adaptor protein, including receptor interacting protein-1 (RIP-1, a serine/threonine kinase), TNF receptor-associated factor 2 (TRAF2, an E3 ubiquitin ligase), and cellular inhibitor of apoptosis protein (cIAP) 1 and cIAP2 [37] [38] [39] . This protein complex is termed complex I, which can activate MAPK kinase kinase-3 (MEKK-3) [40] . Activation of MEKK-3 causes the phosphorylation of inhibitor of κB kinase (IKK), which subsequently phosphorylates the inhibitor of κB (IκB), leading to ubiquitination and degradation of IκB. NF-κB is thus released and then rapidly enters the nucleus to trigger transcription of multiple target genes, including cytokines, chemokines, matrix metalloproteinases (MMPs), a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs), and pro-survival genes [41, 42] . Interestingly, NF-κB is also able to stimulate TNF-α production [21] , thereby providing a positive feedback loop between both factors to further amplify the biological effects of TNF-α.
Stimulation of TNFR1 can also activate apoptosis-signaling kinase-1 (ASK-1), which is a member of the MEKK family and associates with TRAF2 within the complex I. ASK-1 then interacts with MAPK kinase (MEK) 4 and MEK6, which in turn activate c-Jun N-terminal kinase (JNK) and p38 MAPK [43, 44] . This leads tmTNF-α α , and cIAP1/2 are then recruited to TNFR1 to form complex I. On one hand, complex I promotes nuclear translocation of NF-κB via activating MEKK-3 and IKK, leading to transcription of numerous target genes. On the other hand, complex I activates ASK-1 and then interacts with MEK4/6, which activates AP-1 through the JNK/p38 MAPK signaling pathway to induce gene expression. In some instances, complex I is internalized, and converted to complex II which is composed of TRADD, FADD, RIP-1, TRAF2, and pro-caspase 8. Complex II mediates the conversion of pro-caspase 8 into caspase 8, which subsequently induces apoptosis by activating caspase 3. Upon binding with tmTNF-α, TNFR2 recruits TRAF2, TRAF1, TRAF3, and cIAP1/2 to form a complex which also activates NF-κB and AP-1 through a similar downstream signaling cascade stimulated by TNFR1. In addition, activation of TNFR2 activates Etk, which transactivates VEGFR2, resulting in the activation of the PI3K/Akt pathway.
to AP-1 activation and subsequent transcription of many genes. Similar to NF-κB, AP-1 is thought to promote inflammation responses and cell survival. Nevertheless, this signaling pathway also contributes to cell death. In myocardial cells treated with TNF-α, overexpression of ASK-1 promotes apoptosis while TNF-α-induced apoptosis is inhibited by a catalytically inactive form of ASK-1 [45] . Likewise, mouse embryonic fibroblasts lacking ASK-1 are resistant to TNF-α-induced apoptosis [46] .
In addition to these signaling pathways, TNFR1 activates another pathway to regulate cell survival (Fig. 2) . By a largely unknown mechanism, complex I is internalized and a complex containing TRADD, RIP-1, and TRAF2 is released from TNFR1. Fas-associated DD protein (FADD) then binds to TRADD followed by pro-caspase 8 recruitment, leading to formation of complex II, also known as deathinducing signaling complex (DISC). This mediates the transformation of pro-caspase 8 into caspase 8, which subsequently initiates apoptosis by activating caspase 3 [47, 48] . Taken together, activation of TNFR1 by TNF-α mediates numerous signaling pathways involving a number of cellular effects. More TNFR1-dependent signaling pathways may be discovered through future research.
TNFR2-dependent signaling pathways
Since TNFR2 is devoid of a DD in its intracellular region, it cannot bind to TRADD but directly interact with TRAF2, leading to further recruitment of TRAF1, TRAF3, cIAP1, and cIAP2 ( Fig. 2) . Thus, TNFR2 shares signaling effects with TNFR1 such as activation of NF-κB and AP-1, suggesting a cross-talk between the TNFR2 and TNFR1 pathways [49, 50] . TNFR2 was also reported to activate the endothelial/ epithelial tyrosine kinase (Etk), which transactivates vascular endothelial growth factor receptor 2 (VEGFR2). Activation of Etk and VEGFR2 then activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, thereby modulating multiple biological behaviors, including cell adhesion, proliferation, migration, apoptosis, and survival [51] . Collectively, depending on the cell types, TNFR1 and TNFR2 may have distinct, as well as overlapping, roles in signal transduction and gene expression. Signaling through TNFR2 is believed to induce primarily proinflammatory and pro-survival effects.
Expression Pattern of TNF-α in Degenerative IVD Cells and Tissues
TNF-α is primarily synthesized by immune cells such as monocytes and macrophages, but it can also be produced by IVD cells themselves. A low expression of TNF-α, TNFR1, and TNFR2 is observed in non-degenerative IVD cells and tissues, revealing the involvement of TNF-α signaling in normal disc tissue repair and remodeling [52, 53] . However, degenerative and herniated human IVD tissues display higher TNF-α levels than non-degenerative IVD tissues [54] . Likewise, a marked increase in TNF-α levels is seen in degenerative IVD cells [19] . Weiler et al. [55] detected the expression of TNF-α in non-degenerative and degenerative human IVD tissue specimens by the immunohistochemical technique. In non-degenerative IVD tissues, TNF-α is expressed substantially in older adults, whereas it is sparsely expressed in adolescents and young adults, indicating that TNF-α expression increases with age. Moreover, the levels of TNF-α are significantly increased in degenerative IVD tissues when compared with non-degenerative samples, and TNF-α levels show a positive correlation with the degree of disc degeneration. A later study by Bachmeier et al. [56] shows a higher expression of TNF-α in NP tissues compared with AF tissues, suggesting that the distribution of TNF-α within the discs is associated with tissue types. In patients with lumbar disc herniation, more TNF-α-immunoreactive cells are observed in NP samples in comparison with patients with non-painful scoliosis [57] . It is worth noting that TNFR1 and TNFR2 along with TNF-α are comparably expressed in human NP tissues [56] . Furthermore, another study confirms the expression of both TNFR1 and TNFR2 in NP tissues obtained from patients with lumbar disc herniation, with levels of TNFR1 being positively correlated with severity of postoperative pain [58] . Collectively, increased TNF-α expression is not only closely associated with disc degeneration, but also is believed to be causative of the disease.
Roles of TNF-α in IDD
IDD is a complex disease process that begins with changes in the local cellular microenvironment and progresses to impairment of their structure and function [59] . Although the pathogenesis is not fully understood, it has been well established that ECM disruption, inflammatory responses, apoptosis, autophagy, and cell proliferation play critical roles in promoting the development of disc degeneration [60] [61] [62] [63] . Given TNF-α as a pleiotropic cytokine, it is not surprising that this cytokine is involved in all these pathological processes of IDD (Fig. 3) , which will be discussed in detail below.
TNF-α promotes ECM degradation
The progressive breakdown of ECM is the most important pathological feature of IDD [64] . MMPs and ADAMTSs are the primary enzymes that are responsible for ECM degradation. Many members of MMPs and ADAMTSs are highly expressed in degenerative IVD tissues, and their levels are positively correlated with the degree of disc degeneration [65] [66] [67] [68] . In recent years, there has been a large body of evidence indicating that TNF-α can induce the production of MMPs and ADAMTSs. In ex vivo human NP tissues, TNF-α markedly enhances the expression of MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, leading to a significant decrease in aggrecan and Col II contents [69] . Rabbit NP cells, in response to TNF-α, display increased MMP-13 production, with concomitant inhibition of Col II and proteoglycan synthesis [70] . Application of TNF-α to normal AF cells also strongly raises MMP-1 levels [71] . In NP cells, the expression of MMP-3 and MMP-9 is up-regulated to a Figure 3 . TNF-α is involved in multiple pathological processes of disc degeneration TNF-α induces disc degeneration. This pro-inflammatory cytokine promotes the occurrence and development of IDD by accelerating ECM degradation, inflammatory response, apoptosis, autophagy, and cell proliferation.
greater level by IL-1β than by TNF-α, whereas MMP-13 expression is up-regulated by each cytokine to a similar extent [72] . These results support the hypothesis that, while TNF-α may be an important initiating factor in matrix degeneration, IL-1β plays a greater role in established pathological degradation.
Many of the inductive effects of TNF-α on the expression of MMPs and ADAMTSs are mediated by the NF-κB and/or MAPK signaling pathways. Li et al. [73] found that prolyl hydroxylase (PHD) 2 functions as a co-activator of NF-κB p65 to promote matrix catabolism induced by TNF-α. Exposure of NP cells to TNF-α up-regulates the expression of PHD2, which then interacts with NF-κB p65 to stimulate the transcription of MMP-3, MMP-13, and ADAMTS-5 [73] . Similar to PHD2, PHD3 plays a significant role in promoting TNF-α-induced activation of NF-κB and subsequent synthesis of ADAMTS-5 and MMP-13 [74] . On the other hand, LIM mineralization protein-1 abrogates TNF-α-mediated production of MMP-3 and MMP-13 by inhibiting nuclear translocation of NF-κB p65 in NP cells [75] . Bone morphogenetic protein-7 (BMP-7) is a molecule that can stimulate disc matrix synthesis [76, 77] . Addition of BMP-7 to human IVD cells is found to antagonize TNF-α-induced activation of NF-κB and subsequent up-regulation of ADAMTS-4 and ADAMTS-5, leading to decreased degradation of disc matrix macromolecules aggrecan and Col II. This suggests that BMP-7 not only promotes the anabolism of ECM within the discs but also suppresses its catabolism [78] . Kletsas and colleagues [79] revealed a positive correlation between TNF-α and p38 MAPK signaling in bovine NP cells and showed that TNF-α-induced up-regulation of MMP-3 expression is reversed in the presence of p38 MAPK inhibitor. The effects of TNF-α on MMP-1 and MMP-3 expression are also dependent on the activation of JNK [80] . In addition, treatment of human NP cells with TNF-α significantly increases the levels of ADAMTS-4 and ADAMTS-5 and aggrecan cleavage via activating the MAPK and NF-κB signaling pathways [81] . Syndecan 4, a cell surface heparan sulfate proteoglycan, is known to actively control disc matrix catabolism. It has been reported that cooperative signaling through syndecan 4 and the MAPK/NF-κB axis is required for TNF-α-dependent expression of MMP-3 in NP cells [82] . Thus, modulation of these signaling pathways using small molecular inhibitors may provide a novel and promising therapeutic strategy for mitigating the catabolic action of matrix-degrading enzymes and restoring a normal homeostatic balance in ECM production and turn-over.
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs and ADAMTSs. To date, four subtypes have been identified in TIMPs, namely TIMP-1, TIMP-2, TIMP-3, and TIMP-4 [83] . In human NP cells treated with TNF-α, a moderate enhancement of TIMP-1 amount is observed in a p38 MAPKdependent manner, which is accompanied by a more considerable increase in MMP-3 levels, leading to a decreased ratio of TIMP-1 to MMP-3 [84] . However, inhibition of p38 MAPK reverses the effects of TNF-α on the ratio of TIMP-1 to MMP-3 [84] . Thus, although it appears that TIMP-1 expression is up-regulated in the process of disc degeneration to counter the catabolic effects of MMPs, the net result of TNF-α on disc matrix is to stimulate ECM degradation, as illustrated by the decreased ratio of TIMP-1 to MMP-3.
TNF-α amplifies the inflammatory responses
It is well known that inflammation plays a critical role in the pathology of IDD [85, 86] . In addition to affecting ECM homeostasis, TNF-α can stimulate IVD cells to synthesize many pro-inflammatory cytokines, thereby further aggravating the inflammatory state within the discs. TNF-α stimulation has been shown to promote the production of large amounts of IL-6 and IL-8 from human AF cells [87] . Substance P (SP), as a classical neurotransmitter, acts as an inflammatory regulator in other tissue types. When treated with TNF-α, both NP and AF cells increase SP synthesis, which then induces the expression of IL-1β, IL-6, and IL-8 [88] . IL-17, a cytokine predominantly secreted by T helper 17 cells, has a strong pro-inflammatory activity. A recent study by Gruber et al. [89] showed that the levels of IL-17 are positively correlated with severity of disc degeneration, and its production is induced by TNF-α in AF cells. Additionally, in cells isolated from the AF and NP tissues of patients undergoing surgery for IDD, either IL-17 or TNF-α remarkably enhances the release of inflammatory mediators such as IL-6, nitric oxide (NO) and prostaglandin E2 (PGE2), and up-regulates the expression of intercellular adhesion molecule (ICAM-1) [90] . Moreover, addition of TNF-α to IL-17 shows a synergistic increase in the release of these inflammatory mediators and ICAM-1 expression [90] . This suggests that IVD cells not only respond with a catabolic phenotype to IL-17 and costimulant TNF-α, but also express surface ligands with consequent potential to recruit additional lymphocytes and immune cells to the IVD microenvironment.
Chemokines constitute a large family of small proteins and generally have a low molecular weight ranging from 7 to 15 kDa. To date, >50 chemokines and 19 chemokine receptors have been discovered. According to the arrangement of two N-terminal cysteine residues, these chemokines are divided into four subclasses: CXC, CC, C, and CX3C. Corresponding to the four subclasses of chemokines, their receptors are also subdivided into four families, namely CXCR, CCR, CR, and CX3CR. Following binding of chemokines to their receptors, they can recruit immune cells to injured tissues and thus are deeply involved in the development of inflammatory diseases, including IDD [91, 92] . Similar to pro-inflammatory cytokines, TNF-α is also able to regulate the expression of many chemokines within the discs. Recently, Liu et al. [93] performed a bioinformatics analysis of the microarray data on the gene expression profiles of degenerative IVD cells after exposure to TNF-α. They found that a total of 753 genes were differentially expressed, among which CCL20, CCL3, CCL5, CXCL2, and CXCL5 are up-regulated. Consistent with this, IVD cells treated with TNF-α markedly increase the production of CCL5, a chemoattractant for macrophages and eosinophils, and its expression is correlated with both discogenic pain and severity of disc degeneration [94] . Other macrophage chemoattractants, such as CCL3 whose expression also correlates positively with IVD tissue degeneration degree, are induced via activating the MAPK and NF-κB signaling pathways when NP cells are exposed to TNF-α [95] . In addition to these chemokines, stimulation of human AF cells with TNF-α exhibits a significant increase in the levels of CCL2, also known as monocyte chemoattractant protein-1 [96] . This is also demonstrated in rabbit AF and NP cells [97] . Taken together, these studies suggest that TNF-α acts as a key player in amplifying inflammation during disk degeneration.
Sterile inflammation is an inflammatory state triggered by nonmicrobial and microbial activators and trauma [98] . Trauma is also known as a risk factor for disc degeneration. Recently, Dudli et al. [99] have demonstrated that TNF-α expression levels are significantly increased in rabbit NP tissues after trauma. Rajan et al. [100] imitated IDD by stimulating toll-like receptor 4 (TLR-4), a pattern recognition receptor of the innate immune system, with its ligand LPS. They found that TLR-4 activation markedly induces TNF-α secretion and promotes the production of novel inflammatory mediators, such as macrophage migration inhibitory factor (MIF) and high mobility group box 1 (HGMB1), both in vivo and in vitro [100] . Moreover, increased production of MIF and HGMB1 is also achieved by exposure to TNF-α alone [100] . Interestingly, the expressions of TLR-1, TLR-2, TLR-3, and TLR-4 are significantly up-regulated in the presence of TNF-α in human IVD cells, and their levels are enhanced with increased degeneration severity in human IVDs [101] . Collectively, these findings support the notion that TNF-α may play an important role in promoting sterile inflammation within the discs.
TNF-α induces apoptosis of IVD cells
Apoptosis, also termed Type I programmed cell death, is a cellular self-destruction mechanism involved in a number of biological events, such as developmental sculpturing, tissue homeostasis, and the removal of unwanted cells. However, uncontrolled or excessive apoptosis leads to significant loss of IVD cells, which have been shown to be an important contributor to IDD [102, 103] . Currently, there has been a large body of evidence supporting the involvement of TNF-α in IVD cell apoptosis. In NP cells from discogram-proven painful degeneration patients undergoing spine corrective operation by collagenase trypsin, TNF-α significantly increases apoptotic rate and upregulates the expressions of p53 and caspase 3, which are partially reversed by vitamin C administration [104] . This indicates a protective role for vitamin C in controlling TNF-α-induced NP cell apoptosis. Similarly, following exposure of rabbit NP cells to TNF-α, a large number of these cells undergo apoptosis and display morphological changes associated with apoptosis, whereas pretreatment with hepatocyte growth factor blocks TNF-α-induced apoptosis [105] . In addition, overexpression of insulin-like growth factor-1 (IGF) and recombinant pure BMP-7 was found to antagonize NP cell apoptosis stimulated by TNF-α [106, 107] . MicroRNAs (miRNAs) are a class of endogenously expressed, small non-coding RNAs, which can negatively modulate gene expression by targeting mRNAs for translational repression and/or cleavage [108] [109] [110] . It has been demonstrated that miR-494 is highly expressed in degenerative human NP tissues, and knockout of miR-494 protects human NP cells from apoptosis induced by TNF-α through up-regulation of JunD, which is mediated via cytochrome C apoptotic signaling [111] .
In addition to induction of NP cell apoptosis, TNF-α regulates the apoptosis of AF cells. In degenerated human AF tissues, TNF-α levels show a positive correlation with the apoptotic rate of AF cells [112] . Additionally, in a rat model of cervical IDD induced by surgery, electroacupuncture treatment inhibits AF cell apoptosis through suppression of the TNF-α/TNFR1/caspase 8 signaling pathway, suggesting that electroacupuncture may serve as an alternative therapy for the treatment of cervical spondylosis [113] .
TNF-α regulates autophagy
Autophagy is a catabolic process that leads to the autophagosomedependent lysosomal degradation of bulk cytoplasmic contents, abnormal protein aggregates, and excess or damaged organelles. Although primarily cytoprotective, autophagy can also contribute to cell death. A growing body of evidence has demonstrated that autophagy is involved in the pathogenesis of degenerative diseases, such as osteoarthritis, Alzheimer's disease, and IDD [114] [115] [116] . However, the role of autophagy in the process of IDD is still controversial. Some studies suggest autophagy as a protective mechanism [117, 118] . Other reports showed that autophagy promotes the development of IDD [119, 120] . The discrepancy may be caused by differences in the cell culture systems and/or species among the studies. The conflicting results and potential mechanisms need to be further investigated.
TNF-α can induce autophagy in osteoclasts [121] , fibrosarcoma L929 cells [122] , and dopaminergic cells [123] . Recently, studies have focused on the association between TNF-α and autophagy in IVD cells. In comparison with healthy discs, degenerative discs show significantly greater up-regulation of well-recognized autophagy-related genes, including beclin 1 (a marker of early phagophore formation or autophagy initiation), microtubule-associated protein 1 light chain 3/Atg8, Atg12, presenilin 1, and cathepsin B, with concomitant increases in autophagic vacuolization and autophagosomes with complex and redundant whorls of membranederived material [124] . Moreover, incubation of human AF cells with TNF-α markedly raises the levels of autophagy-related genes, such as damage-regulated autophagy modulator 1, p62, PIM-2 (a positive regulator of autophagy) and WIPI49 (linked to starvationinduced autophagy), suggesting that TNF-α is an inducer of AF cell autophagy [124] . In contrast to this study, another study by Xu et al. [125] showed that TNF-α has no effect on autophagy of rat NP cells. These observations indicate that TNF-α-induced autophagy appears to be cell-type dependent.
TNF-α stimulates the proliferation of NP cells
A healthy IVD contains relatively few cells and these cells are sparsely distributed. A characteristic feature of disc degeneration is the appearance of cell clusters, particularly in damaged areas [126] . Since NP cells are the most important cells within the discs, aberrant proliferation of these cells has been considered as the main cause of cell cluster formation, which plays a crucial role in IDD [127] . A variety of factors, such as leptin [128] , platelet-derived growth factor [129] , IGF-1 [129] , and thymosin beta-4 [130] , have been reported to modulate NP cell proliferation. Similar to these factors, TNF-α is also related to the proliferation of NP cells. Following treatment of human NP cells with TNF-α, significant increases in cell viability and number, as well as in cyclin B1 levels are observed, indicating enhancement of cell proliferation [131] . Mechanistically, activation of the NF-κB, JNK, and p38 MAPK pathways is involved in TNF-α-induced proliferation of human NP cells [131] . Activation of the Notch signaling pathway has been reported to promote IVD cell proliferation [132] . A study from Wang et al. [133] showed that TNF-α up-regulates the expression of Notch1 and Notch2 receptors along with their ligand Jagged-2, and target genes HES1, HEY1, and HEY2 in rat NP cells. They also found that the levels of Notch2 are higher in degenerative human IVD tissues than those in nondegenerative IVD tissues [133] . Thus, in addition to the NF-κB, JNK, and p38 MAPK pathways, TNF-α may also promote NP cell proliferation through the Notch signaling.
TNF-α and Disc Herniation
Disc herniation is defined as localized NP material that protrudes beyond the margins of the disc space, with local pain and/or sciatica. It can be resulted from a sudden injury such as trauma or progressive degenerative changes as a result of the cumulative effect of repetitive stresses. Biomechanical studies have demonstrated that failure rarely occurs by axial compression alone and that flexion and torsion are also important contributors to the development of disc herniation in both acute trauma and degenerative changes [134] . In addition, the exposure of the immune-privileged NP tissues triggers an autoimmune response involving macrophages, neutrophiles, T cells, and B cells, as well as proinflammatory cytokines such as IL-1β which plays an important role in the pathogenesis of disc herniation [60] . The comparison of IDD and disc herniation is presented in Table 1 .
Like IDD, TNF-α is closely associated with disc herniation. TNF-α levels are significantly increased in IVD samples derived from recurrent lumbar disc herniation patients and positively correlate with postoperative sciatic pain severity [135] . Moreover, there is accumulating evidence which indicates that TNF-α aggravates disc herniation by amplifying inflammatory responses and decreasing IVD cell viability [136, 137] . Of note, TNF-α also contributes to natural resolution of disc herniation. It is well established that a portion of disc herniation patients do not develop symptoms of chronic LBP and radiculopathy due to neutrophil and macrophage-mediated timely resorption of the extruded NP tissues [138] . A recent study by Haro et al. [139] has shown that TNF-α is required to induce MMP-7 in herniated NP tissues, which acts as a chemoattractant for macrophages necessary for resorption. Immunoreactivity to TNF-α in the dorsal root ganglion (DRG) is increased following exposure to NP material in a rat model of disc herniation [140] . Application of TNF-α inhibitor during surgery markedly prevents macrophage infiltration and vascular cell adhesion molecule-1 expression in the DRG [141] . These findings suggest that TNF-α may play a critical role in the coordination of macrophage infiltration following herniation of NP tissues. Thus, the effects of TNF-α on disc herniation are complex and controversial. These conflicting results and potential mechanisms need to be further investigated.
Therapeutic Potential of Targeting TNF-α in IDD
Given the fact that TNF-α is a key contributor to IDD, inhibition of TNF-α could be a viable approach for the treatment of early-stage disc degeneration. Indeed, the monoclonal antibody of TNF-α significantly decreases the concentration and activity of MMP-1 and MMP-3 in ex vivo IVD tissues isolated from disc herniation patients [142] . Co-incubation of TNF-α with nanomolar doses of sTNFR2, an endogenous TNF-α inhibitor, also attenuates the secretion of NO and PGE2 in a dose-dependent manner, suggesting that sTNFR2 holds potential for mitigating inflammation in IDD pathology [143] . Infliximab is a chimeric bivalent IgG1 monoclonal antibody against TNF-α. In degenerated human NP cells, TNF-α elevates the contents of IL-1β, IL-6, and IL-8, which are inhibited by infliximab when added at the same time as TNF-α stimulation [144] . Thus, anti-TNF-α therapy for degenerative disc disease may be most effective when applied early in the inflammatory process.
IDD constitutes the pathological foundation of most musculoskeletal disorders of the spine, including spinal stenosis, instability, disk herniation, radiculopathy, and myelopathy. Importantly, anti-TNF-α treatments for LBP and radicular pain have entered clinical trials to evaluate their efficacy. Etanercept, a chimeric antibody and infusion drug, first appeared as an anti-TNF-α antibody. In a multicenter, randomized, double-blind, placebo-controlled trial, two transforaminal epidural injections of etanercept lead to clinically significant reductions in mean daily worst leg pain and worst back pain at 4 weeks post-treatment when compared with placebo for subjects with symptomatic lumbar disc herniation, without obvious adverse safety concerns observed [145] . In a prospective randomized study, epidural injection of etanercept into spinal nerves is more effective than dexamethasone for alleviating LBP, leg pain, and leg numbness in patients with lumbar spinal stenosis [146] . In patients with subacute lumbosacral radiculopathy, two transforaminal epidural injections of etanercept show significant improvements in leg and back pain 1 month after treatment [147] . Similarly, perispinal administration of etanercept to degenerative disc disease patients markedly reduces back pain, sciatica, and neck pain at 20 min, 1 day, 1 week, 2 weeks, and 1 month [148] . In contrast to these studies, Cohen et al. [149] reported that in a 1-month follow-up, administration of etanercept through two epidural injections does not produce pain relief compared with placebo, and has less efficacy than epidural steroid treatment for improving pain and functionality in patients with lumbosacral radiculopathy. Additionally, Korhonen et al. [150] have demonstrated that the beneficial effect of a single intravenous infusion of 3 mg/kg of infliximab for disc herniationinduced sciatica is sustained in most patients over a 1-year followup period. The same research group, however, observed that in a randomized, controlled, 3-month follow-up study, a single intravenous infusion of either 3 mg/kg of infliximab or placebo shows no significant difference in improving leg pain in patients with disc herniation-induced sciatica [151] . Like infliximab, adalimumab is also a monoclonal antibody against TNF-α. In patients experiencing acute and severe sciatica due to lumbar disc herniation, subcutaneous injections of adalimumab (40 mg) at 7-day intervals result in small but significant improvement in leg pain and fewer surgical procedures in short term, and markedly decrease the need for back surgery in a 3-year follow-up [152, 153] . Together, these clinical studies suggest that anti-TNF-α treatments might be beneficial to relieve LBP and radicular pain, although the efficacy is still controversial. Larger studies with longer follow-up are needed to confirm their benefits in the future. In addition to direct prevention of TNF-α, the protective effects of many therapeutic modalities for disc degeneration are associated with inhibition of TNF-α-mediated biological actions. In a rabbit model of disc degeneration, administration of niacinamide effectively alleviates TNF-α-induced destruction and synthesis inhibition of matrix ingredients in AF tissues [154] . In TNF-α-treated AF cells isolated from porcine IVD tissues, treatment with platelet-rich plasma (PRP) that is extracted from whole blood and riches in mixed growth factors markedly inhibits MMP-1 expression and increases the production of ECM components, such as aggrecan and Col II [155] . PRP also shows a similar effect in human NP cells via inhibiting MMP-3 [156] . These observations suggest that PRP may have important therapeutic application in the management of disc degeneration. Transforming growth factor-β1 (TGF-β1) has a potent anabolic effect on NP cells. A recent study by Yang et al. [157] has demonstrated that addition of TGF-β1 to rat NP cells abolishes TNF-α-mediated up-regulation of Col I and MMP-3 expression and down-regulates aggrecan and Col II expression, which is associated with inhibition of the ERK1/2 pathway. Also, TGF-β1 in combination with IL-10 remarkably reduces TNF-α production and suppresses the development of inflammatory responses [158] . Plasma-mediated radiofrequency-based ablation is an electrosurgical technique currently used for tissue removal in a wide range of surgical applications, including lumbar microdiscectomy. It is suggested that plasma-mediated radiofrequency-based ablation can stimulate disc proteoglycan and IL-8 production and maintain annulus architecture, depending on decreased TNF-α production [159] . Dickkopfrelated protein 1 (DKK1) is a potent inhibitor of Wnt/β-catenin signaling. Blockage of the Wnt/β-catenin signaling pathway by DKK1 has been shown to counteract TNF-α-induced production of MMP-13 in rabbit NP cells, leading to increased synthesis of Col II and proteoglycan [70] . Adipose-derived stromal cells (ADSCs) contribute to disc integrity. When human NP cells were cultured in compressive load at 3.0 MPa for 48 h with ADSCs co-culture, ADSCs protect against compressive load-induced apoptosis and ECM degradation partially through inhibition of TNF-α synthesis [160] . Additionally, the protective effects of low-level light therapy against degenerative human NP cells are primarily derived from its abilities to antagonize IL-6 and IL-8 secretion induced by TNF-α [161] .
Targeting TNF-α-dependent signaling pathways is another attractive therapeutic strategy for mitigating disc degeneration and has shown promise. Crocin, a bioactive component of saffron, has been found to exert anti-inflammatory effects on cartilage. When rat NP cells are exposed to crocin, the MAPK signaling pathway is inactivated due to suppression of JNK phosphorylation, which leads to down-regulation of catabolic enzymes (MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5) and pro-inflammatory cytokines (IL-1β and IL-6) followed by a significant increase in aggrecan and Col II contents [162] . In a rat model of lumbar IDD, administration of curcumin reduces the release of inflammatory factors by inhibiting NF-κB activation, thereby decelerating the process of degeneration [163] . In injured rat discs by repeated puncturation, treatment with an IKKβ inhibitor suppresses NF-κB nuclear translocation and then attenuates the production of IL-1β, TNF-α, and IL-6, suggesting a therapeutic potential of NF-κB inactivation in degenerative disc disease [164] .
Conclusions and Future Directions
As a master pro-inflammatory cytokine, TNF-α is highly expressed in degenerative IVD tissues, and can accelerate the progression of disc degeneration, involving matrix degradation, inflammatory responses, apoptosis, autophagy, and cell proliferation. Although several clinical trials have suggested that inhibition of TNF-α may have considerable promise in the treatment of LBP and radicular pain, challenges remain to be resolved with this monotherapy. A degenerative IVD is in a chronic inflammatory state, and many proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 are involved in the process [85] . The net result of these cytokine networks is to cause an imbalance between catabolism and anabolism within the disc, leading to its degeneration, herniation, and radicular pain. It is not unreasonable to assume that inhibition of only one pro-inflammatory factor is difficult to fully stop the progress of IDD and thus achieves limited clinical efficacy. Recently, several clinical studies showed that either anti-IL-1β or anti-IL-6 treatments also contribute to back and radicular pain relief [165, 166] . Given that TNF-α is only a contributor to disc degeneration, it is likely that TNF-α inhibitors in combination with anti-IL-1β and/or anti-IL-6 drugs are more effective than a single medication in the treatment of IDD. However, the safety and efficacy of combined strategies require to be tested in clinical settings. Since IVDs are the largest avascular structures in the body with limited transport, there is an urgent need to establish ideal in vivo delivery systems of anti-TNF-α drugs for clinical application. Recently, Likhitpanichkul et al. [167] reported that direct mixing of infliximab into genipin cross-linked fibrin shows steady and sustained release of infliximab over 20 days. Moreover, genipin cross-linked fibrin as drug carrier is adhesive, injectable, and slowly-degrading hydrogel with the potential to seal AF defects. Thus, drug-loaded genipin cross-linked fibrin may be simple, feasible, and effective for the delivery of anti-TNF-α drugs directly to painful IVDs. In answering these and many other questions, we will increase our chances to develop TNF-α-centered therapy to promote biologically-induced disc repair and improve the prognosis of patients with degenerative disc disease and LBP, thereby providing an alternative to surgical intervention for early-stage disc degeneration.
